ENVUE MEDICAL INC
FEEDNASDAQTrading Snapshot
- Day Range
- $1.02 – $1.04
- 52-Week Range
- $0.29 – $5.98
- Volume
- $2.64B
- Avg Volume
- $2.53B
- Shares Outstanding
- 774,722
- Next Earnings
- Oct 29, 2026
Fundamentals Snapshot
- Annual Revenue
- $3M
- Last Q Revenue
- $239,000
- P/E Ratio
- -0.0
- P/S Ratio
- 0.4x
- EPS (TTM)
- $-40.87
- Dividend Yield
- 0.00%
- Dilution (1yr)
- +2605.6%
Why Investors Own FEED
- ✓High-growth profile — revenue up +14.3% YoY with expanding US Equity exposure.
- ✓Healthy economics — 47% gross margin and 18% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
ENVUE MEDICAL INC
FEED
StockOtter · stockotter.spaceAbout ENVUE MEDICAL INC
NanoVibronix, Inc. focuses on developing non-surgical medical devices that stimulate biological responses. Its core offerings include UroShield and PainShield. The company's business activities span across several global markets, such as the United States, Europe, Australia, India, and Israel, in addition to other territories. This enterprise was founded by Harold Jacob and Jona Zumeris in September 2003, and its main corporate office is situated in Tyler, Texas.
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Analyst Price Target
ⓘLatest News & Updates
Nanovibronix, Inc. (NASDAQ:FEED) Stock Short Interest Drops 81.6%
Nanovibronix, Inc. (NASDAQ: FEED - Get Free Report) was the recipient of a significant decrease in short interest during the month of September. As of September 15th, there was short interest totaling 16,107 shares, a de
ENvue Medical Provides Nasdaq Listing Update
TYLER, Texas, Sept. 15, 2026 (GLOBE NEWSWIRE) -- ENvue Medical, Inc. (Nasdaq: FEED) (“ENvue” or the “Company”), a medical technology company focused on innovative solutions for enteral feeding and therapeutic ultrasound,
ENvue Medical Resumes U.S. Commercial Shipments of NanoVibronix PainShield® and Begins Fulfilling Open Distributor Orders
TYLER, Texas, Sept. 09, 2026 (GLOBE NEWSWIRE) -- ENvue Medical , Inc. (NASDAQ: FEED) (“ENvue” or the “Company”), a commercial-stage medical device company focused on real-time guided bedside feeding tube placement and th
ENvue Medical Selected to Exhibit ENvue™ Navigation Platform at Vizient Innovative Technology Exchange
TYLER, Texas, Sept. 02, 2026 (GLOBE NEWSWIRE) -- ENvue Medical (NASDAQ: FEED) (“ENvue” or the “Company”), a commercial-stage medical device company focused on real-time guided bedside feeding tube placement, today announ
ENvue Medical Announces Exclusive UroShield® Distribution Agreement with Minimum Purchase Commitments of Approximately $2.6 Million
Multi-year agreement with Peak Medical expands UroShield commercialization across the United Kingdom and Republic of Ireland Multi-year agreement with Peak Medical expands UroShield commercialization across the United Ki
ENvue Medical Secures Equity Financing Facility of Up to $50 Million to Support Commercial Growth, Technology Expansion and Strategic Acquisitions
TYLER, Texas, Aug. 12, 2026 (GLOBE NEWSWIRE) -- ENvue Medical, Inc. (NASDAQ: FEED) ("ENvue" or the "Company"), a commercial-stage medical technology company, today announced that it has entered into a securities purchase